Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1974 1
1975 1
1986 3
1987 1
1990 4
1995 1
2000 5
2003 1
2004 2
2005 2
2007 1
2008 3
2010 2
2011 7
2012 3
2013 1
2014 9
2015 6
2016 8
2017 6
2018 6
2019 5
2020 4
2021 4
2022 3
2023 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Cohen EEW, et al. Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Lancet. 2019. PMID: 30509740 Clinical Trial.
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Vermorken JB, et al. Among authors: kawecki a. N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656. N Engl J Med. 2008. PMID: 18784101 Free article. Clinical Trial.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Müller-Richter U, Kiyota N, Roberts M, Khan TA, Miller-Moslin K, Wei L, Argiris A. Haddad RI, et al. Among authors: kawecki a. J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332. Epub 2022 Dec 6. J Clin Oncol. 2023. PMID: 36473143 Free PMC article. Clinical Trial.
Narrow-band imaging vs Lugol chromoendoscopy in screening for esophageal squamous cell neoplasia: a randomized trial.
Chaber-Ciopinska A, Kiprian D, Wieszczy P, Bielasik A, Bugajski M, Januszewicz W, Jarzabski A, Niemiec M, Mroz A, Kawecki A, Regula J, Kaminski MF. Chaber-Ciopinska A, et al. Among authors: kawecki a. Pol Arch Intern Med. 2023 Oct 26;133(10):16462. doi: 10.20452/pamw.16462. Epub 2023 Mar 14. Pol Arch Intern Med. 2023. PMID: 36916462 Free article. Clinical Trial.
Management of complicated monochorionic twin pregnancies.
Degenhardt J, Enzensberger C, Tenzer A, Kawecki A, Kohl T, Axt-Fliedner R. Degenhardt J, et al. Among authors: kawecki a. Z Geburtshilfe Neonatol. 2015 Feb;219(1):22-7. doi: 10.1055/s-0034-1382002. Epub 2015 Mar 3. Z Geburtshilfe Neonatol. 2015. PMID: 25734474 Review.
New Graphene Composites for Power Engineering.
Knych T, Mamala A, Kwaśniewski P, Kiesiewicz G, Smyrak B, Gniełczyk M, Kawecki A, Korzeń K, Sieja-Smaga E. Knych T, et al. Among authors: kawecki a. Materials (Basel). 2022 Jan 18;15(3):715. doi: 10.3390/ma15030715. Materials (Basel). 2022. PMID: 35160658 Free PMC article.
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study.
Klinghammer K, Fayette J, Kawecki A, Dietz A, Schafhausen P, Folprecht G, Rottey S, Debourdeau P, Lavernia J, Jacobs A, Ahrens-Fath I, Dietrich B, Baumeister H, Zurlo A, Ochsenreither S, Keilholz U. Klinghammer K, et al. Among authors: kawecki a. ESMO Open. 2021 Oct;6(5):100242. doi: 10.1016/j.esmoop.2021.100242. Epub 2021 Sep 2. ESMO Open. 2021. PMID: 34482179 Free PMC article. Clinical Trial.
Tracheal adenoid cystic carcinoma mimicking a thyroid tumor: A case report.
Kukwa W, Korzeń P, Wojtowicz P, Sobczyk G, Kiprian D, Kawecki A, Kukwa A, Krzeski A, Szczylik C, Czarnecka AM. Kukwa W, et al. Among authors: kawecki a. Oncol Lett. 2014 Sep;8(3):1312-1316. doi: 10.3892/ol.2014.2282. Epub 2014 Jun 25. Oncol Lett. 2014. PMID: 25120714 Free PMC article.
80 results